Cookie Policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read ourPrivacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

Interventional Cardiology

Products

Solutions

 

 

Mastering Rapid and Healthy Vascular Repairhttp://www.terumo-europe.com/en-emea/clinicaldata/mastering-rapid-and-healthy-vascular-repairMastering Rapid and Healthy Vascular RepairPushing the boundaries of science and medical engineering for the improvement of health: Ultimaster combines an optimal balance between stent design for ultimate conformability with simultaneous polymer resorption and drug release, to match the procedure-triggered biological response in the vessel.(1) This results in optimal vessel recovery and potentially shortened DAPT time.(2)HayabusaArticlePage
CENTURY II Trial highlightshttp://www.terumo-europe.com/en-emea/clinicaldata/century-iiCENTURY II Trial highlightsMulticentre, intercontinental study - 58 sites in 13 countries across Europe, Japan, and South Korea - Primary endpoint: Freedom from TLF at 9 months - Secondary endpoint: rate of TVF; patient-oriented composite endpoint; rate of TLR, TVR, ST, cardiac death, MI; composite of cardiac death and MI; rate of bleeding and vascular complications - Clinical follow-up up to 5 years HayabusaArticlePage
DISCOVERY 1TO3 Trialhttp://www.terumo-europe.com/en-emea/clinicaldata/discovery-1to3-trialDISCOVERY 1TO3 Trial60 MVD patients with OFDI, single arm, primary endpoint TLF @ 12M. Ongoing.HayabusaArticlePage

 

 

 

 

 

 

First patient enrolled in major new study investigating abbreviated DAPT post-stent in high bleeding risk patientshttp://www.terumo-europe.com/en-emea/news/first-patient-enrolled-in-major-new-study-investigating-abbreviated-dapt-post-stent-in-high-bleeding-risk-patientsFirst patient enrolled in major new study investigating abbreviated DAPT post-stent in high bleeding risk patientsEmmen, The Netherlands03/04/2017 22:00:00
Terumo Completes Acquisition of Vascular Closure Business and Other Assets of Abbott and St. Jude Medicalhttp://www.terumo-europe.com/en-emea/news/terumo-completes-acquisition-of-vascular-closure-business-and-other-assets-of-abbott-and-st-jude-medicalTerumo Completes Acquisition of Vascular Closure Business and Other Assets of Abbott and St. Jude MedicalTokyo, Japan20/01/2017 23:00:00
Terumo Signs to Acquire Vascular Closure Business and Other Assets of St. Jude Medical and Abbotthttp://www.terumo-europe.com/en-emea/news/terumo-signs-to-acquire-vascular-closure-business-and-other-assets-of-st-jude-medical-and-abbottTerumo Signs to Acquire Vascular Closure Business and Other Assets of St. Jude Medical and AbbottTokyo, Japan06/12/2016 23:00:00

 

 

PCR London Valves 2017http://www.terumo-europe.com/en-emea/Events/PCR London Valves 2017.aspxPCR London Valves 2017United Kingdom23/09/2017 22:00:0026/09/2017 12:50:00Londonhttp://www.pcrlondonvalves.com/, http://www.pcrlondonvalves.com/
CCT 2017http://www.terumo-europe.com/en-emea/Events/CCT 2017.aspxCCT 2017Japan25/10/2017 22:00:0028/10/2017 12:58:00Kobehttps://cct.gr.jp/meetings.html, https://cct.gr.jp/meetings.html